Literature DB >> 24646011

Current approach to iron chelation in children.

Yesim Aydinok1, Antonis Kattamis, Vip Viprakasit.   

Abstract

Transfusion-dependent children, mostly with thalassaemia major, but also and occasionally to a more significant degree, with inherited bone marrow failures, can develop severe iron overload in early life. Moreover, chronic conditions associated with ineffective erythropoiesis, such as non-transfusion-dependent thalassaemia (NTDT), may lead to iron overload through increased gut absorption of iron starting in childhood. Currently, the goal of iron chelation has shifted from treating iron overload to preventing iron accumulation and iron-induced end-organ complications, in order to achieve a normal pattern of complication-free survival and of quality of life. New chelation options increase the likelihood of achieving these goals. Timely initiation, close monitoring and continuous adjustment are the cornerstones of optimal chelation therapy in children, who have a higher transfusional requirements compared to adults in order to reach haemoglobin levels adequate for normal growth and development. Despite increased knowledge, there are still uncertainties about the level of body iron at which iron chelation therapy should be started and about the appropriate degree of iron stores' depletion.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  chelation; children; iron; sickle; thalassaemia

Mesh:

Substances:

Year:  2014        PMID: 24646011     DOI: 10.1111/bjh.12825

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

Authors:  Patricia M Fortin; Karen V Madgwick; Marialena Trivella; Sally Hopewell; Carolyn Doree; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-09

Review 2.  Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease.

Authors:  Satheesh Chonat; Charles T Quinn
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

3.  Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study.

Authors:  Selen Bayraktaroglu; Nihal Karadas; Sebnem Onen; Deniz Yılmaz Karapinar; Yesim Aydinok
Journal:  Ann Hematol       Date:  2022-01-05       Impact factor: 3.673

Review 4.  Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

Authors:  Patricia M Fortin; Sheila A Fisher; Karen V Madgwick; Marialena Trivella; Sally Hopewell; Carolyn Doree; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2018-05-08

5.  Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.

Authors:  Sefika Pinar Senol; Eyup Naci Tiftik; Selma Unal; Aydan Akdeniz; Bahar Tasdelen; Bahar Tunctan
Journal:  J Basic Clin Pharm       Date:  2016-03

6.  Iron Overload and Platelet Function Defects: Possible Correlation.

Authors:  Abdulkader A Dahi; Ehab Hanafy; Mohammed Al Pakra
Journal:  J Investig Med High Impact Case Rep       Date:  2016-10-26

7.  Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience.

Authors:  Alkistis Adramerina; Nikoleta Printza; Emmanouel Hatzipantelis; Symeon Symeonidis; Labib Tarazi; Aikaterini Teli; Marina Economou
Journal:  Biology (Basel)       Date:  2022-02-05

Review 8.  Is the Benefit-Risk Ratio for Patients with Transfusion-Dependent Thalassemia Treated by Unrelated Cord Blood Transplantation Favorable?

Authors:  Tang-Her Jaing
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.